Sara Montemuiño Muñiz*, Soraya Marcos Sánchez, Julia Calzas Rodríguez, Beatriz Losada Vila, Esther Llorente Herrero, María Dolores Hisado Díaz, Victoria Valeri-Busto González, Begoña Taboada Valladares, Blanca Vaquero Barrón, Francisco José Marcos Jimenez, Sergio Amor Alonso, Javier Moradiellos, Núria Rodríguez de Dios, Felipe Couñago

Muñiz et al. J Clin Transl Res 2021; 7(2):13

Published online: April 16, 2021

Abstract

Background and aim: In stage IIIA-N2 non-small cell lung cancer (NSCLC), the accuracy of combined positron-emission tomography/computed tomography imaging (PET-CT), together with mediastinal staging techniques, has led to a wide range of challenging clinical scenarios in terms of therapeutic management. Concurrent chemoradiotherapy followed by consolidation immunotherapy remains the standard of care. In patients with potentially-resectable disease, surgery plays an important role in multimodal therapy. The introduction of targeted therapies and immune-checkpoint inhibitors have revolutionized multimodal treatment. In the present article, we review current treatment options and future trends in stage IIIA-N2 NSCLC.
Relevance for patients: This article provides insight into the current status of multimodal treatment for NSCLC to support decision-making in routine clinical practice.

DOI: http://dx.doi.org/10.18053/jctres.07.202102.013

Author affiliation

1. Department of Radiation Oncology. Hospital Universitario de Fuenlabrada. Camino del Molino, 2, 28942, Fuenlabrada, Madrid. Spain. Sara Montemuiño
2. Department of Medical Oncology. Hospital Universitario de Fuenlabrada. Camino del Molino, 2, 28942, Fuenlabrada, Madrid, Spain.
3. Department of Nuclear Medicine. Hospital Universitario de Fuenlabrada. Camino del Molino, 2, 28942, Fuenlabrada, Madrid, Spain.
4. Department of Pulmonology. Hospital Universitario de Fuenlabrada. Camino del Molino, 2, 28942, Fuenlabrada, Madrid, Spain.
5. Department of Radiation Oncology. Complexo Hospitalario Universitario Santiago de Compostela, Choupana s/n, bloque d. Santiago de Compostela, A Coruña, Spain.
6. Department of Radiation Oncology, Hospital Universitario de La Princesa, C/ Diego de León, 62, 28006, Madrid, Spain.
7. Department of Radiation Oncology, Hospital Universitario de Cáceres. Avda. Universidad 75, 10004, Cáceres, Extremadura. Spain.
8. Department of Thoracic Surgery. Hospital Universitario Quirónsalud Madrid. C/ Diego de Velázquez, 1, 28223, Pozuelo de Alarcón. Madrid. Spain.
9. Department of Radiation Oncology. Hospital del Mar. Passeig Marítim, 25-29, 08003 Barcelona, Spain.
10. IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain. 11. Pompeu Fabra University. Barcelona. Doctor Aiguader, 80, 08003 Barcelona.
12. Department of Radiation Oncology. Hospital Universitario Quirónsalud Madrid. C/ Diego de Velázquez, 1, 28223, Pozuelo de Alarcón. Madrid. Spain.
13. Hospital La Luz. Calle del Maestro Ángel Llorca 8, 28003, Madrid. Spain.
14. Universidad Europea de Madrid. Calle Tajo, s/n, 28670 Villaviciosa de Odón, Madrid. Spain.

*Corresponding Author
Sara Montemuiño Muñiz
Department of Radiation Oncology, Hospital Universitario de Fuenlabrada, Camino del Molino, 2, 28942, Fuenlabrada, Madrid.
 Tel: +34 916006740.
Email: sara.montemuino@salud.madrid.org

Handeling editor:
Michal Heger
Department of Pharmaceutics, Utrecht University, the Netherlands
Department of Pharmaceutics, Jiaxing University Medical College, Zhejiang, China

Downloads

Full text PDF